Abstract
Various morphometric characteristics of microvessels, highlighted by means of anti-CD34 immunohistochemical staining, were evaluated in the bone marrow of 52 patients with chronic myeloid leukemia (CML) in chronic phase, in relation to several clinicopathologic parameters. Twenty control bone marrows and 15 cases of CML in blastic phase were also studied. Microvessel density (MVD), total vascular area (TVA) and several size- and shape-related parameters were quantitated in the region of most intense vascularization using image analysis. Overall, the group of chronic phase CML had higher MVD and size-related parameters and more branching microvessels than controls. Blastic phase was characterized by increased numbers of microvessels with a rounder shape and smaller caliber than chronic phase. A positive correlation emerged between marrow fibrosis and MVD as well as between white blood cell counts and rounder vessel sections. No relationship existed between microvascular parameters and Hasford or Sokal prognostic scores. In univariate analysis, overall and progression-free survival were adversely affected by MVD, size-related parameters, increased platelet count, age and spleen size. Multivariate analysis indicated that microvessel area was related to progression-free survival, whereas both MVD and area were significant prognosticators of overall survival, even when Hasford or Sokal scores are introduced into the model. Our data suggest that changes in angiogenic parameters may participate in the conversion of normal marrow to CML and ultimately to blastic transformation. More importantly, MVD and microvessel caliber are significant predictors of patient survival and progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Folkman, J. Clinical applications of research on angiogenesis. N Engl J Med, (1995). 333, 1757–1763.
Schnitt, SJ The real value of angiogenesis research in breast cancer. Adv Anat Path, (1997). 4, 23–27.
Srivastava, A, Laidler, P, Davies, RP, Horgan, K & Hughes, LE The prognostic significance of tumor vascularity in intermediate-thickness (0.76–4.0 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol, (1988). 133, 419–423.
Korkolopoulou, P, Konstantinidou, AE, Kavantzas, N, Patsouris, E, Pavlopoulos, PM, Christodoulou, P, Thomas-Tsagli, E & Davaris, P Morphometric microvascular characteristics predict prognosis in superficial and invasive bladder cancer. Virch Arch, (2001). 438, 603–611.
Brawer, MK, Deering, RE, Brown, M, Preston, SD & Bigler, SA Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer, (1994). 73, 678–687.
Pavlopoulos, PM, Konstantinidou, AE, Agapitos, E, Kavantzas, N, Nikolopoulou, P & Davaris, P A morphometric study of neovascularization in colorectal carcinoma. Cancer, (1998). 83, 2067–2075.
Yamazaki, K, Abe, S, Tagekawa, H, Sukoh, N, Watanabe, N, Ogura, S, Nakajima, I, Isobe, H, Inoue, K & Kawakami, Y Tumor angiogenesis in human lung adenocarcinoma. Cancer, (1994). 74, 2245–2250.
Bruyn, PPH, Breen, PC & Thomas, TB The microcirculation of the bone marrow. Anat Rec, (1970). 168, 55–68.
Mangi, MH Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol, (2000). 111, 43–51.
Choi, K, Kennedy, M, Kazarov, A, Papadimitriou, JC & Keller, G A common precursor for hematopoietic and endothelial cells. Development, (1998). 125, 725–732.
Yamaguchi, H, Ishii, E, Saito, S, Tashiro, K, Fujita, I, Yoshidani, S, Ohtubo, M, Akazawa, K & Miyazaki, S Umbilical vein endothelial cells are an important source of c-kit and stem cell factor which regulate the proliferation of haemopoietic progenitor cells. Br J Haematol, (1996). 94, 606–611.
Fiedler, W, Graeven, U, Ergn, S, Verago, S, Kilie, N, Stockschlader, M & Hossfeld, DK Vascular endothelial growth factor, a possible paracrine growth factor, in human acute myeloid leukemia. Blood, (1997). 89, 1870–1875.
Vacca, A, Ribatti, D, Roncali, L, Ranieri, G, Serio, G, Silvestris, F & Dammacco, F Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol, (1994). 87, 503–508.
Ribatti, D, Vacca, A, Nico, B, Fanelli, M, Roncali, L & Dammacco, F Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and structural study. Eur J Haematol, (1996). 56, 45–53.
Perez-Atayde, AR, Sallan, SE, Tedrow, V, Connors, S, Allred, E & Folkman, J Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol, (1997). 150, 815–821.
Aguayo, A, Kantarjian, H, Manshouri, T, Gidel, C, Estey, E, Thomas, D, Koller, C, Estror, Z, O’Brien, S, Keating, M, Freireich, E & Albitar, M Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, (2000). 96, 2240–2245.
Padrö, T, Ruiz, S, Bieker, R, Burger, H, Steins, M, Kienast, J, Buchner, T, Berdel, WE & Mesters, RM Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood, (2000). 95, 2637–2644.
de Bont, ESJM, Rosati, S, Jacobs, S, Kamps, WA & Vellenga, E Increased bone marrow vascularization in patients with acute myeloid leukemia: a possible role for vascular endothelial growth factor. Br J Haematol, (2001). 113, 296–304.
Aguayo, A, Estey, E, Kantarjian, H, Manshouri, T, Gidel, C, Keating, M, Giles, F, Estror, Z, Barlogie, B & Albitar, M Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, (1999). 94, 3717–3721.
Aguayo, A, O’Brien, S, Keating, M, Manshouri, T, Gidel, C, Barlogie, B, Beran, M, Keller, C, Kantarjian, H & Albitar, M Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood, (2000). 96, 768–770.
Salven, P, Orpana, A, Teerenhovi, L & Joensuu, H Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and βFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: a single-institution study of 200 patients. Blood, (2000). 96, 3712–3718.
Lundberg, LG, Lerner, R, Sundelin, P, Rogers, R, Folkman, J & Palmblad, J Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascularity. Am J Pathol, (2000). 157, 15–19.
Verstovsek, S, Kantarjian, H, Manshouri, T, O’Brien, S, Faderl, S, Talpaz, M, Cortes, J & Albitar, M Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer, (2002). 94, 1517–1521.
Gunsilius, E, Duba, HC, Petzer, AL, Kahler, CM, Grunewald, K, Stockhammer, G, Gabl, C, Dirnhofer, S, Clausen, J & Gastl, G Evidence from a leukemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet, (2000). 355, 1688–1691.
Harris, NL, Jaffe, ES, Diebold, J, Flandrin, G, Muller-Hermenlink, HK, Vardiman, J, Lister, TA & Bloomfield, CD The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology, (2000). 36, 69–87.
Hasford, J, Pfirrmann, M, Hehlmann, R, Allan, NC, Baccarani, M, Johanna, C, Nelemans, K, Alimena, G, Steegmann, JL & Ansari, H A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst, (1998). 90, 850–858.
Sokal, J, Cox, E, Baccarani, M, Tura, S, Gomez, GA, Robertson, JE, Tso, CY, Braun, TJ, Clarkson, BD, Cervantes, F & Rozman, C the Italian Cooperative CML Study Group Prognostic discrimination in ‘good risk’ chronic granulocytic leukemia. Blood, (1984). 63, 1352–1357.
Mesa, RA, Hanson, CA, Rajkumar, V, Schroeder, G & Tefferi, A Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood, (2000). 96, 3374–3380.
Pruneri, G, Bertolini, F, Soligo, D, Carboni, N, Cortelezzi, A, Ferucci, PF, Buffa, R, Lambertenghi-Deliliers, G & Pezzela, F Angiogenesis in myelodysplastic syndromes. Br J Cancer, (1999). 81, 1398–1401.
Shi, SR, Key, ME & Kalra, K Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem, (1991). 39, 741–748.
Hsu, SM, Raine, L & Fanger, H Use of avidin–biotin–peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem, (1981). 29, 577–580.
Vermeulen, PB, Gasparini, G, Fox, SB, Toi, M, Martin, L, McCulloch, P, Pezzela, F, Viale, G, Weidner, N, Harris, AL & Dirix, LY Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer, (1996). 32, 2474–2484.
Weidner, N, Folkman, J, Pozza, F & Bevilacqua, P Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst, (1992). 84, 1875–1887.
Fox, E & Ulrich, C Sigma Scan Image Measurement Software, User's Electronic Manual. (1995). Sigma Scan, Jandel Scientific: Erkrath, Germany
Branemark, P-I Bone marrow microvascular structure and function. Adv Microcirc, (1968). 1, 1–65.
Korkolopoulou, P, Apostolidou, E, Pavlopoulos, PM, Kavantzas, N, Vyniou, N, Thymara, I, Terpos, E, Patsouris, E, Yataganas, X & Davaris, P Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia, (2001). 15, 1369–1376.
Benjamin, LE & Keshet, E Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA, (1997). 94, 8761–8766.
Patan, S, Munn, LL & Jain, PK Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res, (1996). 51, 260–272.
Garcia-Monzon, C, Sanchez-Madrid, F, Garcia-Buey, L, Garcia-Arroyo, A, Garcia-Sanchez, A & Moreno-Otero, R Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology, (1995). 108, 231–241.
Bellamy, WT, Richter, L, Sirjani, D, Roxas, C, Glinsmann-Gibson, B, Frutiger, Y, Grogan, TM & List, AF VEGF is an autocrine promoter of abnormal localized immature myeloid precursors and leukemic progenitor formation in myelodysplastic syndromes. Blood, (2001). 97, 1427–1434.
Green, AR Hemangioblast origin of chronic myeloid leukaemia?. Lancet, (2000). 355, 1659–1660.
Rajkumar, SV, Leong, T, Roche, PC, Fonseca, R, Dispenzieri, A, Lacy, M, Lust, JA, Witzig, TE, Kyle, RA, Gertz, MA & Greipp, PR Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res, (2000). 6, 3111–3116.
Zhong, H, De Marzo, AM, Laughner, E, Lim, M, Hilton, DA, Zagzag, D, Buechler, P, Isaacs, WB, Scmenza, GL & Simons, JW Overexression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res, (1999). 59, 5830–5835.
Rajkumar, SV, Dispenzieri, A, Fonseca, R, Lacy, MR, Geyer, S, Lust, JA, Kyle, RA, Greipp, PR, Gertz, MA & Witzig, TE Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia, (2001). 15, 1274–1276.
Barosi, G, Grossi, A, Comotti, B, Musto, P, Gamba, G & Marchetti, M Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol, (2001). 114, 78–83.
Raza, A, Meyer, P, Dutt, D, Zorat, F, Lisak, L, Nascimben, F, du Randt, M, Kaspar, C, Goldberg, C, Loew, J, Dar, S, Gezer, S, Venugopal, P & Zeldis, J Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, (2001). 98, 958–965.
Harris, AL Antiangiogenesis for cancer therapy. Lancet, (1997). 349, 13–15.
Druker, BJ & Lydon, NB Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest, (2000). 105, 3–7.
Acknowledgements
We thank Miss Evie Delicha for the statistical analysis of results.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Korkolopoulou, P., Viniou, N., Kavantzas, N. et al. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia 17, 89–97 (2003). https://doi.org/10.1038/sj.leu.2402769
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402769
Keywords
This article is cited by
-
Reconfiguration and loss of peritubular capillaries in chronic kidney disease
Scientific Reports (2023)
-
TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
Leukemia (2016)
-
Improved prediction of clinical outcome in chronic myeloid leukemia
International Journal of Hematology (2015)
-
Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immunoexpression
BMC Cancer (2014)
-
Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia
Medical Oncology (2012)